184 related articles for article (PubMed ID: 31580749)
1. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
Crawford ED; Twardowski PW; Concepcion RS; Hafron JM; Harris RG; Moul JW; Gordan LN; Petrylak DP; Atkinson SN; Boldt-Houle DM; Keane TE; Higano CS; Henderson RJ; Kader AK; Hussain MH; Shore ND
J Urol; 2020 Apr; 203(4):743-750. PubMed ID: 31580749
[TBL] [Abstract][Full Text] [Related]
2. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
Crawford ED; Hafron JM; Tagawa ST; Twardowski PW; Harris RG; Moul JW; Keane TE; Concepcion RS; Higano CS; Gordan LN; Petrylak DP; Cross CK; Kader AK; Shore ND
J Urol; 2021 Feb; 205(2):554-560. PubMed ID: 33090917
[TBL] [Abstract][Full Text] [Related]
3. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
4. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
6. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
7. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
Oefelein M
J Urol; 2003 Jan; 169(1):251-5. PubMed ID: 12478147
[TBL] [Abstract][Full Text] [Related]
8. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
9. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
10. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
11. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
Raddin RS; Walko CM; Whang YE
Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
[TBL] [Abstract][Full Text] [Related]
12. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
13. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Oefelein MG; Cornum R
J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
[TBL] [Abstract][Full Text] [Related]
14. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
15. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
[TBL] [Abstract][Full Text] [Related]
16. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
19. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
